Search

Displaying results 6271 - 6280 of 10000 in total
  1. Drug

    Betaxolol

    go.drugbank.com/drugs/DB00195
    ApprovedInvestigational

    A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.

  2. Drug

    D-JNKI-1

    go.drugbank.com/drugs/DB05660
    Investigational

    A synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the organ of Corti during times of ox...

  3. Drug

    TAK-475

    go.drugbank.com/drugs/DB05317
    Investigational

    TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.

  4. Drug

    NasoVAX

    go.drugbank.com/drugs/DB15859
    Investigational

    As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230). … The compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a nearly 6-fold cellular immune response in comparison to an injectable vaccine[L16313].

  5. Drug

    Palivizumab

    go.drugbank.com/drugs/DB00110
    ApprovedInvestigational

    Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).

  6. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders.

  7. Drug

    Arbaclofen

    go.drugbank.com/drugs/DB08891
    Investigational

    It is believed to be a selective gamma-amino butyric acid type B receptor agonist, and has been investigated as a treatment for autism spectrum disorder and fragile X syndrome in randomized, double blind

  8. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  9. Drug

    Mepartricin

    go.drugbank.com/drugs/DB13633
    Investigational

    Categories: Drugs Used in Benign Prostatic Hypertrophy
  10. Drug

    GlycoPEG-GCSF

    go.drugbank.com/drugs/DB06022
    Experimental

    GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.